The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer

Obstetrics and Gynecology

Volumn 116, Issue 1, 2010, Pages 76-84

  Castle, Philip E ^a   Fetterman, Barbara ^b   Thomas Cox, J ^b   Shaber, Ruth ^b   Poitras, Nancy ^b   Lorey, Thomas ^b   Kinney, Walter ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ARTICLE; CANCER RISK; CANCER SCREENING; COLPOSCOPY; DNA DETERMINATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; NONHUMAN; PAPANICOLAOU TEST; PRECANCER; PRIORITY JOURNAL; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

ADULT; AGE FACTORS; COLPOSCOPY; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PRECANCEROUS CONDITIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 77954052979     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181e3e719     Document Type: Article

References (26)

1. Wright TC Jr, Schiffman M. Adding a test for human papillo-mavirus DNA to cervical-cancer screening. N Engl J Med 2003;348:489-490
2. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-362 (Pubitemid 35446606)
3. Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304-309
4. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-2119
5. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ, ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cyto-logical abnormalities. JAMA 2002;287:2120-2129
6. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008;111:167-177
7. Siebers AG, Klinkhamer PJ, Grefte JM, Massuger LF, Vedder JE, Beijers-Broos A, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA 2009;302: 1757-1764
8. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, et al. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007;11:201-222
9. Schlesselman JJ. Case-control studies: design, conduct, analysis. New York (NY): Oxford University Press; 1982.
10. Sherman ME, Castle PE, Solomon D. Cervical cytology of atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H): characteristics and histologic outcomes. Cancer 2006;108:298-305.
11. Ronco G, Cuzick J, Segnan N, Brezzi S, Carozzi F, Folicaldi S, et al. HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer 2007;43:476-480
12. Human papillomavirus testing for triage of women with cyto-logic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. J Natl Cancer Inst 2000;92:397-402.
13. Schiffman M, Adrianza ME. ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol 2000;44:726-742
14. Castle PE, Rodriguez AC, Burk RD, Herrero R, Hildesheim A, Solomon D, et al. Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. Int J Cancer 2009;125:1649-1656
15. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet Gynecol 2010;115:243-248
16. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-299 (Pubitemid 32219816)
17. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1383-1392
18. Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squa-mous cells of undetermined significance. Obstet Gynecol 2007;109:1325-1331
19. Castle PE, Stoler MH, Solomon D, Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS Report. Am J Clin Pathol 2007;127: 805-815
20. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008; 337:a1284.
21. Kovacic MB, Castle PE, Herrero R, Schiffman M, Sherman ME, Wacholder S, et al. Relationships of human papillomavi-rus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 2006;66:10112-10119
22. Safaeian M, Schiffman M, Gage J, Solomon D, Wheeler CM, Castle PE. Detection of precancerous cervical lesions is differential by human papillomavirus type. Cancer Res 2009;69: 3262-3266
23. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-632
24. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernan-dez-Avila M, Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009;199:936-944
25. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-935
26. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and pre-cancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-314